Related Experiment Videos
Anticardiolipin antibodies in a case of neuro-Behçet with superior vena caval occlusion
Clinical Rheumatology
|March 1, 1987
Insights
Anticardiolipin antibodies may cause superior vena cava occlusion in neuro-Behçet patients. This condition might be linked to reduced fibrinolysis, suggesting a key pathogenic role for these antibodies.
Area of Science:
- Cardiovascular Medicine
- Immunology
- Rheumatology
Background:
- Behçet's disease is a rare multisystem inflammatory disorder.
- Neuro-Behçet specifically affects the nervous system.
- Superior vena cava (SVC) occlusion is a serious complication.
Observation:
- A 55-year-old male patient with neuro-Behçet presented with SVC occlusion.
- High titers of anticardiolipin antibodies were detected in his serum.
- The patient also exhibited decreased fibrinolysis.
Findings:
- The presence of anticardiolipin antibodies and reduced fibrinolysis were noted.
- These factors are implicated in the pathogenesis of SVC occlusion in this patient.
Implications:
- Anticardiolipin antibodies may contribute to venous thrombosis in Behçet's disease.
- Therapeutic strategies targeting antibody production or fibrinolysis could be beneficial.
- Further research is needed to elucidate the precise mechanisms involved.
Abstract:
The patient, a 55-year-old man with neuro-Behçet, developed superior vena caval occlusion. Antibodies to cardiolipin were detected in high titres in his serum and a decreased fibrinolysis was also found. It is suggested that anticardiolipin antibodies, perhaps decreasing fibrinolysis, may play an important pathogenic role in some patients with Behçet's disease.